Core Insights - Wanze Co., Ltd. has been recognized for its outstanding performance in the fields of micro-ecological medicine and high-temperature alloys, winning two significant awards at the 2025 China Listed Company Brand Value List Conference [1] - The company's dual business strategy of "medical + high-end manufacturing" has proven successful, showcasing its ability to innovate and develop across high-barrier industries [1][4] Company Development - Wanze Co., Ltd. has evolved from a single business focus in real estate at its inception in 1992 to a dual-driven model, fully divesting from real estate in 2019 to concentrate on its core areas [1] - The company has made strategic decisions aligned with national policies, particularly in the context of domestic substitution and the Healthy China initiative [4] Financial Performance - In 2024, Wanze's subsidiary, Wanze Shuangqi Pharmaceutical, achieved revenues of 794 million yuan, a year-on-year increase of 13.43%, with net profits reaching 330 million yuan, up 39.8% [4] - The company has significantly increased its R&D investment, reaching 209 million yuan in 2024, a growth of 27.48%, and has accumulated 228 patents [5] Market Opportunities - The domestic aviation engine market is rapidly growing, with less than 30% self-sufficiency in high-end materials, positioning Wanze to capitalize on domestic substitution opportunities [7] - The global micro-ecological drug market exceeds one trillion dollars, with core products like "Jin Shuangqi" and "Ding Junsheng" expanding into new indications to unlock further growth [7] Strategic Initiatives - Wanze Co., Ltd. is actively integrating resources in the aviation engine and micro-ecological sectors through acquisition funds, enhancing technical collaboration and market influence [7] - The company aims to transition from a traditional micro-ecological product supplier to a comprehensive "microbial medical solution provider" through a forward-looking "three-dimensional innovation strategy" [7]

Core Viewpoint - Wanze Co., Ltd. has been recognized with two prestigious awards, "Annual Private Leading Brand" and "Classic Brand Case," at the 2025 Ninth China Listed Company Brand Value List Conference, highlighting its brand strength, innovation, and industry influence [1][2]. Group 1: Company Overview - Wanze Co., Ltd. is a leading player in the pharmaceutical micro-ecology field and one of the few private enterprises in China capable of full-process research and development from high-temperature alloy materials to component manufacturing [1][2]. - The company’s subsidiary, Inner Mongolia Shuangqi, is the only national high-tech enterprise focused on digestive and gynecological micro-ecological systems, with its core products "Jin Shuangqi®" and "Ding Junsheng®" leading their respective markets [2]. Group 2: Financial Performance - In 2024, Wanze Co., Ltd. achieved a revenue of 1.079 billion yuan, a year-on-year increase of 9.93%, and a net profit attributable to shareholders of 193 million yuan, up 9.17% [3]. - For Q1 2025, the company reported a revenue of 335 million yuan and a net profit of approximately 72.69 million yuan, reflecting year-on-year growth rates of 15.34% and 10.52%, respectively [3]. Group 3: Research and Development - In 2024, Wanze Co., Ltd. invested 209 million yuan in R&D for high-temperature alloys, marking a significant increase of 27.48% year-on-year [5]. - The company has established a research team with a high proportion of master's and doctoral graduates, enhancing its capabilities in aerospace engine material research [5]. Group 4: Future Strategy - The company aims to enhance its R&D, production, and market expansion efforts, focusing on micro-ecology and high-temperature alloys to create greater shareholder value and contribute to industry development [6].